Exploring a new treatment for retinal diseases using a specific agonist
Official title: Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease models
Funded at University of Minnesota · NIH-11006269 · Data updated 2026-11-12
This study is exploring a new treatment that could help protect and heal the retina, which is important for good vision, and it might lead to better options for people with eye conditions like diabetic retinopathy and macular degeneration.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | January 1, 2022 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $453,631 |
| NIH project number | 5R01EY033316-04 |
| Project ID | NIH-11006269 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from retinal diseases such as diabetic retinopathy, uveitis, or other conditions affecting the blood-retina barrier.
✕Less likely to help
Patients with retinal diseases not related to blood-retina barrier dysfunction may not benefit from this research.
What this research studies
This research investigates a novel agonist that targets the Frizzled4 and LRP5 receptors to restore function to the blood-retina barrier, which is crucial for retinal health. By using various mouse models that mimic different retinal diseases, the study aims to understand how this agonist can activate signaling pathways that protect and repair the retina. Patients may benefit from insights gained about potential new therapies for conditions like diabetic retinopathy and macular degeneration.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve vision and quality of life for patients with retinal diseases.
How similar studies have gone: While the approach of using a Frizzled4/LRP5 agonist is novel, similar strategies targeting blood-brain and blood-retina barriers have shown promise in preliminary studies.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Junge, Harald — University of Minnesota
- Study coordinator: Junge, Harald
Related research
Other NIH-funded projects on the same topics.
-
Integrative Curation of Clinically Relevant Variants in X-Linked Inherited Retinal Disease Genes
A project to expand expert review of genetic variants linked to X‑linked inherited retinal diseases so patients can access gene therapies.
-
Intravitreal gene therapy for inherited retinal disease
A specialized gene therapy approach delivered inside the eye is being studied to help children with inherited retinal diseases maintain or improve vision.
-
Retinal Disease: Molecular Basis and Pathophysiology
A gene mutation linked to retinal disease is studied to understand how it changes cellular pathways and leads to vision problems.
-
Genes that change how inherited retinal disorders behave
This work looks for other genes that change how CRB1-related inherited retinal diseases affect children and adults who carry CRB1 mutations.
-
A new antibody drug to restore the retina’s protective barrier
This project tests a novel antibody designed to boost a natural signaling pathway to strengthen the retina’s protective barrier for people with retinal diseases that cause leaking or inflammation.
-
Eye-injection gene therapy for inherited retinal disease
A gene therapy delivered by an injection into the eye aims to treat inherited forms of retinal degeneration, including in children.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.